Related Experiment Video
Updated: Mar 19, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Shintaro Iwasaki1, Stephen N Floor1, Nicholas T Ingolia1
1Department of Molecular and Cell Biology, Center for RNA Systems Biology, University of California, Berkeley, California 94720, USA.
Abstract:
Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumour cells and repress translation of specific messenger RNAs. RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its messenger RNA selectivity is proposed to reflect highly structured 5' untranslated regions that depend strongly on eIF4A-mediated unwinding. However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these drugs actually increase the affinity between eIF4A and RNA. Here we show that secondary structure in 5' untranslated regions is only a minor determinant for RocA selectivity and that RocA does not repress translation by reducing eIF4A availability. Rather, in vitro and in cells, RocA specifically clamps eIF4A onto polypurine sequences in an ATP-independent manner. This artificially clamped eIF4A blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein expression from transcripts bearing the RocA-eIF4A target sequence. In elucidating the mechanism of selective translation repression by this lead anti-cancer compound, we provide an example of a drug stabilizing sequence-selective RNA-protein interactions.
Insights
Rocaglamide A (RocA) selectively kills cancer cells by targeting eukaryotic initiation factor 4A (eIF4A). This drug clamps eIF4A onto specific RNA sequences, disrupting protein synthesis and reducing cancer cell expression.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- Rocaglamide A (RocA) inhibits protein synthesis and selectively targets aneuploid tumor cells.
- RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent RNA helicase, with proposed selectivity for structured mRNA 5' untranslated regions.
- Previous hypotheses suggested RocA represses translation by reducing eIF4A availability or targeting structured mRNA regions.
Purpose of the Study:
- To elucidate the precise mechanism by which RocA selectively represses translation.
- To investigate the role of mRNA secondary structure and eIF4A availability in RocA's mechanism of action.
- To determine how RocA achieves selectivity in targeting specific messenger RNAs.
Main Methods:
- In vitro biochemical assays to study eIF4A-RNA interactions.
- Cell-based experiments to assess translation repression and protein expression.
- Analysis of RocA's effect on eIF4A binding affinity and RNA helicase activity.
Main Results:
- RocA's selectivity is not primarily determined by mRNA 5' untranslated region secondary structure.
- RocA does not repress translation by decreasing eIF4A availability.
- RocA acts by clamping eIF4A onto polypurine sequences in an ATP-independent manner, blocking 43S scanning and causing premature translation initiation.
Conclusions:
- RocA selectively represses translation by stabilizing a sequence-specific interaction between eIF4A and polypurine sequences.
- This mechanism leads to upstream translation initiation and reduced protein expression from targeted transcripts.
- The study provides a novel example of a drug stabilizing sequence-selective RNA-protein interactions for therapeutic effect.
Related Concept Videos
Leaky Scanning
Bacterial Protein Maturation
Improving Translational Accuracy
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Translational Regulation

